A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Current Status and Progress on Diagnosis and Treatment of Malignant Peritoneal Mesothelioma
2020
Zhongliu Fangzhi Yanjiu
Preserved Fulltext
Malignant peritoneal mesothelioma(MPM) is a rare and aggressive tumor and highly associated with asbestos exposure. Due to the wide application of asbestos materials in the early stage, the incidence of MPM is increasing now. The symptoms of MPM are atypical, so most of patients are in the late stage when diagnosed. And the prognosis is so poor that the median survival time is only 12 months. Now the main treatment of MPM is CRS-HIPEC, at the same time, a number of immune and targeted
doi:10.3971/j.issn.1000-8578.2020.20.0384
doaj:565044377b4b4fdeafcd9f535f476b52
fatcat:w3gtlnaskzfolmuqkvhmm327vy